ClinicalTrials.gg
Active, not recruitingNCT03778957EMERALD-1Updated Jul 15, 2026

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

A Phase 3 interventional study of Durvalumab and Bevacizumab in Hepatocellular Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 166 sites in 18 countries. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
724
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing durvalumab in Carcinoma, Hepatocellular — 22 open to participants now, 32 under way, 4 of them phase 3. durvalumab · Carcinoma, Hepatocellular.

Enrollment
3rd of 42
724 · median 37
Started
2018
with 1 other
Phase 3
5 of 42
1 open now
Primary completion
2023-09
later than 3 of 31 live
Registered
6th of 42
by date
Lead sponsor
7 of 42
AstraZeneca

Among the 42 studies testing durvalumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 3, reaches primary completion later than 3 of the 31 other live ones, and was the 6th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

22 of the 42 studies testing durvalumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing durvalumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study to determine the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE given with durvalumab plus bevacizumab therapy compared to TACE therapy alone in patients with locoregional hepatocellular carcinoma not amenable to curative therapy

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
  • TACE
  • Durvalumab
  • Bevacizumab
  • Liver Cancer
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • No evidence of extrahepatic disease
  • Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
  • score class A to B7 and (ECOG) performance status of 0 or 1 at enrollment
  • by Modified Response Criteria in Solid Tumors () criteria
  • Adequate organ and marrow function

Key Exclusion Criteria

  • Any history of nephrotic or nephritic syndrome
  • cardiovascular disease or history of arterioembolic event including a stroke or myocardial infarction, unstable angina, cerebrovascular accident, or within 6 months prior to randomization
  • Any prior or current evidence of coagulopathy or bleeding diathesis or patients who had any kind of surgery in the past 28 days ( are exempt from this exclusion)
  • History of abdominal fistula or GI perforation, non healed gastric ulcer that is to treatment, or active GI bleeding within 6 months prior to enrollment
  • Patients with Vp3 and Vp4 portal vein thrombosis on baseline imaging are excluded
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
724 participants (actual)

Study arms

  • Experimental
    Arm A

    Transarterial Chemoembolization (TACE) in combination with Durvalumab

    Drug: Durvalumab · Other: Placebo · Procedure: Transarterial Chemoembolization (TACE)

  • Experimental
    Arm B

    Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab

    Drug: Durvalumab · Drug: Bevacizumab · Procedure: Transarterial Chemoembolization (TACE)

  • Placebo comparator
    Arm C

    Transarterial Chemoembolization (TACE) in combination with Placebos

    Other: Placebo · Procedure: Transarterial Chemoembolization (TACE)

Interventions

  • Durvalumab IV (intravenous)

    Also known as: MEDI4736

  • Bevacizumab IV (intravenous)

    Also known as: AVASTIN

  • OtherPlacebo

    Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)

  • ProcedureTransarterial Chemoembolization (TACE)

    TACE (chemo and embolic agent injection into the hepatic artery)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) for Arm B vs Arm C

    PFS per Blinded Independent Central Review (BICR) assessment will be defined as the time from the date of randomization until the date of first objective disease progression or death

    Time frame: Approximately 5 years

Secondary outcomes

  1. Progression Free Survival (PFS) for Arm A vs Arm C

    PFS per Blinded Independent Central Review (BICR) assessment will be defined as the time from the date of randomization until the date of first objective disease progression or death

    Time frame: Approximately 5 years

  2. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause

    Time frame: Approximately 5 years

  3. Health status/quality of life measured by European Organization for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-C30)

    Collection of patient reported outcome (PRO) measures to assess time to deterioration in global health status/quality of life (QoL), functioning (physical) and symptoms

    Time frame: Approximately 5 years

  4. Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)

    Collection of patient reported outcome (PRO) measures to assess time to deterioration in symptoms

    Time frame: Approximately 5 years

Other outcomes

  1. Safety of Durvalumab and Bevacizumab as evaluated by summary of adverse events by treatment arm and CTCAE grade

    Time frame: Approximately 5 years

  2. Immunogenicity of Durvalumab and Bevacizumab as measured by presence of anti-drug antibodies (ADAs)

    Time frame: Approximately 5 years

  3. Pharmacokinetics (PK) of Durvalumab and Bevacizumab as determined by peak serum concentrations

    Time frame: Approximately 5 years

07

Study locations

166 sites
  • Research Site
    Costa Mesa, California 92627, United States
  • Research Site
    La Jolla, California 92093-0698, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Honolulu, Hawaii 96819, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Rochester, Minnesota 55905-0001, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Dallas, Texas 75216, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Benowa, 4217, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Liverpool, 2170, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01323-903, Brazil
  • Research Site
    Vitória, 29043-272, Brazil
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100036, China
  • Research Site
    Beijing, 100069, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Fuzhou, 350005, China
  • Research Site
    Fuzhou, 350025, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210002, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Neijiang, 641100, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 201508, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenzhen, 518053, China
  • Research Site
    Tianjin, 300170, China
  • Research Site
    Wuhan, 430010, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhuhai, 519000, China
  • Research Site
    Bobigny, 93000, France
  • Research Site
    Clichy, 92210, France
  • Research Site
    Grenoble, 38043, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nice, 06202, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Vandœuvre-lès-Nancy, 54511, France
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Bangalore, 560068, India
  • Research Site
    Bengaluru, 560076, India
  • Research Site
    Hyderabad, 500004, India
  • Research Site
    Kolkata, 700054, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Madurai, 625107, India
  • Research Site
    Mumbai, 400 012, India
  • Research Site
    Nashik, 422002, India
  • Research Site
    Pune, 411004, India
  • Research Site
    Surat, 395002, India
  • Research Site
    Vijayawada, 520002, India
  • Research Site
    Visakhapatnam, 530017, India
  • Research Site
    Arezzo, 52100, Italy

Showing the first 100 of 166 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Zotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. PubMed 39798579 ↗
  • Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1:137-149. doi: 10.1002/hep.31424. Epub 2020 Nov 6. No abstract available. PubMed 32557715 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2023, 57 months.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 57 months is close to that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2018
First posted
Dec 19, 2018
StartActual
Nov 30, 2018
Primary completionActual
Sep 11, 2023
CompletionEst.
Aug 31, 2026
Results delay requested
Aug 27, 2024
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03778957
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Nov 30, 2018
Primary completion
Sep 11, 2023
Completion
Aug 31, 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Bruno Sangro, MD
principal investigator · Clinica Universidad de Navarra
Riccardo Lencioni, MD FSIR EBIR
principal investigator · University of Pisa / Miami Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Bevacizumab

Start the discussion